Tim West
YOU?
Author Swipe
View article: Author Correction: Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets
Author Correction: Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets Open
View article: Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study
Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study Open
Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symp…
View article: Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment
Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment Open
View article: Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals Open
INTRODUCTION Plasma biomarkers’ utility for predicting incident mild cognitive impairment (MCI) remains unclear. We evaluated associations of plasma Alzheimer's disease (AD) biomarkers and amyloid positron emission tomography (PET) with tr…
View article: Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment
Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment Open
Objective The diagnostic performance of the Amyloid Probability Score 2 (APS2) - the algorithmic result of the PrecivityAD2™ blood test - was originally trained and validated in two cohorts of cognitively impaired (CI) individuals. Using a…
View article: Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia
Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia Open
INTRODUCTION Plasma biomarkers sensitive to Alzheimer's disease (AD) proteinopathy prior to the onset of dementia have significant implications for early detection. METHODS In 304 individuals without dementia, we investigated whether C 2 N…
View article: Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET
Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET Open
INTRODUCTION Limited data exist on the utility of plasma biomarkers to predict incident abnormal amyloid positron emission tomography (PET). In this study we evaluate the association of plasma Alzheimer's disease (AD) biomarkers with amylo…
View article: Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study
Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study Open
Objective: The objective of this study was to assess clinical decision-making associated with the use of a multi-analyte blood biomarker (BBM) test among patients presenting with signs or symptoms of mild cognitive impairment or dementia. …
View article: Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care
Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care Open
Background An accurate blood test for Alzheimer’s disease (AD) could streamline the diagnostic work‐up and treatment of AD. Our aim was to evaluate an AD blood test in primary and secondary care, using predefined biomarker cutoffs and pros…
View article: Predicting PET‐Based Amyloid and Tau Pathology Stages With Plasma Biomarkers in Alzheimer's disease
Predicting PET‐Based Amyloid and Tau Pathology Stages With Plasma Biomarkers in Alzheimer's disease Open
Background We aimed to investigate whether the quantitative analysis of plasma biomarkers could distinguish the pathology stages indicated by positron emission tomography (PET)‐based Thal phase of amyloid and Braak stage of tau. Method A t…
View article: Diagnostic Performance of Plasma Biomarkers for A/T/N Image Classification in Alzheimer's disease
Diagnostic Performance of Plasma Biomarkers for A/T/N Image Classification in Alzheimer's disease Open
Background We aimed to validate the ability of Alzheimer’s disease plasma biomarkers to predict clinical diagnosis and the ability to predict image‐based A/T/N biomarkers positivity in Asian population. We also sought to define the optimal…
View article: PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology Open
Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities…
View article: Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care Open
Importance An accurate blood test for Alzheimer disease (AD) could streamline the diagnostic workup and treatment of AD. Objective To prospectively evaluate a clinically available AD blood test in primary care and secondary care using pred…
View article: PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations that are Used with Plasma Amyloid-β42/40 in a Multiple Analyte Assay with Algorithm for Detecting Brai
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations that are Used with Plasma Amyloid-β42/40 in a Multiple Analyte Assay with Algorithm for Detecting Brai Open
Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging moda…
View article: Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial Open
INTRODUCTION In trials of amyloid‐lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under‐inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emis…
View article: A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease Open
Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen binds to an iron-responsive element in APP mRNA and decrea…
View article: Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid Open
BACKGROUND With the availability of disease‐modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receivi…
View article: Blood Biomarkers Improve The Diagnostic Accuracy Of Alzheimer’s Disease As Compared With Current Diagnostic Standard In the Primary Care Setting
Blood Biomarkers Improve The Diagnostic Accuracy Of Alzheimer’s Disease As Compared With Current Diagnostic Standard In the Primary Care Setting Open
Background The first and final level of care for most individuals with cognitive impairment is primary care. The aim was to examine the diagnostic accuracy of plasma phospho‐tau217/non‐phospho‐Tau217 (p‐tau217 Ratio) and Aβ42/40 Ratio for …
View article: Detection of Early Alzheimer’s disease at AdventHealth: A Davos Alzheimer’s Collaborative flagship site
Detection of Early Alzheimer’s disease at AdventHealth: A Davos Alzheimer’s Collaborative flagship site Open
Background Early identification of Alzheimer’s disease (AD) is critical for disease‐modifying therapies. The Davos Alzheimer’s Collaborative flagship program tested the feasibility of implementing a digital cognitive assessment (DCA) follo…
View article: Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans
Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans Open
Study Objectives Given the established racial disparities in both sleep health and dementia risk for African American populations, we assess cross-sectional and longitudinal associations of self-report sleep duration (SRSD) and daytime sle…
View article: Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease
Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease Open
INTRODUCTION Incorporating blood‐based Alzheimer's disease biomarkers such as tau and amyloid beta (Aβ) into screening algorithms may improve screening efficiency. METHODS Plasma Aβ, phosphorylated tau (p‐tau)181, and p‐tau217 concentratio…
View article: A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment Open
Objective The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (Preci…
View article: Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA‐FAIM cohort
Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA‐FAIM cohort Open
Introduction It is critical to develop more inclusive Alzheimer's disease (AD) research protocols to ensure that historically excluded groups are included in preclinical research and have access to timely diagnosis and treatment. If valida…
View article: Self‐report sleep duration associates with plasma Aβ42/40 rate of change in late middle‐aged, African American Adults
Self‐report sleep duration associates with plasma Aβ42/40 rate of change in late middle‐aged, African American Adults Open
Background Sleep abnormalities may play a prominent role in the pathogenesis or exacerbation of Alzheimer’s disease (AD). Sleep is considered a modifiable target for prevention and treatment. Racial sleep health disparities exist, and may …
View article: Independent study demonstrates amyloid probability score accurately indicates amyloid pathology
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology Open
Background The amyloid probability score (APS) is the model read‐out of the analytically validated mass spectrometry‐based PrecivityAD ® blood test that incorporates the plasma Aβ42/40 ratio, ApoE proteotype, and age to identify the likeli…
View article: Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease Open
Background: Participant eligibility for the A4 Study was determined by amyloid PET imaging. Given the disadvantages of amyloid PET imaging in accessibility and cost, blood-based biomarkers may serve as a sufficient biomarker and more cost-…
View article: Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 Open
Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid be…
View article: Comparison of plasma and <scp>CSF</scp> biomarkers in predicting cognitive decline
Comparison of plasma and <span>CSF</span> biomarkers in predicting cognitive decline Open
Objectives Concentrations of amyloid‐β peptides (Aβ42/Aβ40) and neurofilament light (NfL) can be measured in plasma or cerebrospinal fluid (CSF) and are associated with Alzheimer’s disease brain pathology and cognitive impairment. This stu…
View article: A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer's disease dementia
A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer's disease dementia Open
Introduction As Alzheimer's disease (AD) biomarkers rapidly develop, tools are needed that accurately and effectively communicate risk of AD dementia. Methods We analyzed longitudinal data from >10,000 cognitively unimpaired older adults. …
View article: Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light Open
Models predicting brain amyloidosis using a high-performance plasma Aβ42/Aβ40 assay may provide an accurate and consistent measure of brain amyloidosis across AA and NHW groups, but models based on plasma p-tau181, p-tau231, and NfL may pe…